Conor Donnelly

ORCID: 0009-0007-0826-8107
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Bayesian Methods and Mixture Models
  • Ovarian cancer diagnosis and treatment
  • PARP inhibition in cancer therapy
  • Renal Transplantation Outcomes and Treatments
  • Statistical Methods and Inference
  • Endometrial and Cervical Cancer Treatments
  • Drug Solubulity and Delivery Systems
  • Mechanical Circulatory Support Devices
  • Organ Transplantation Techniques and Outcomes
  • Genetic factors in colorectal cancer
  • Statistical Methods and Bayesian Inference
  • Statistical Distribution Estimation and Applications
  • Analytical Chemistry and Chromatography
  • Childhood Cancer Survivors' Quality of Life
  • Crystallization and Solubility Studies
  • Transplantation: Methods and Outcomes
  • Textile materials and evaluations
  • Prostate Cancer Diagnosis and Treatment
  • Fatigue and fracture mechanics
  • Hemodynamic Monitoring and Therapy
  • Bone health and osteoporosis research
  • Behavioral and Psychological Studies
  • Emergency and Acute Care Studies
  • Orthopaedic implants and arthroplasty
  • Liver Disease and Transplantation

New York University
2025

NYU Langone Health
2025

Miami Transplant Institute
2024-2025

AstraZeneca (United Kingdom)
2023-2024

McMaster University
2023

Queen's University Belfast
2014-2017

ExxonMobil (United States)
2012

University of Pennsylvania
2010

Shannon N. Westin Kathleen N. Moore Hye Sook Chon Jung‐Yun Lee Jessica Thomes Pepin and 95 more Michael J. Sundborg Ayelet Shai Joseph de la Garza Shin Nishio Michael A. Gold Ke Wang Kristi McIntyre Todd D. Tillmanns Stephanie V. Blank Jihong Liu Michael McCollum Fernando Contreras Mejía Tadaaki Nishikawa Kathryn P. Pennington Zoltán Novàk Andréia Cristina de Melo Jalid Sehouli Dagmara Klasa-Mazurkiewicz Christos Papadimitriou Marta Gil-Martín Birutė Brasiūnienė Conor Donnelly Paula Michelle del Rosario Xiaochun Liu Els Van Nieuwenhuysen Sophia Frentzas Ganessan Kichendasse Bo Gao Tarek Meniawy Linda Mileshkin Gary Richardson Felicia Roncolato Jean‐François Baurain Maryam Bourhaba Eveline Cuypere Philip R. Debruyne Hannelore Denys Frédéric Forget Brigitte Honhon E. Joosens Els Van Nieuwenhuysen Vanessa da Costa Miranda Andréia Cristina de Melo Joao Daniel Guedes Charles Andreé Joseph de Pádua Nicolas Lazaretti Carolina Martins Vieira André Mattar Daniela Neves Palmeiro Christina Pimentel Oppermann Kussler Pedro Emanuel Rubini Liedke João Soares Nunes Katsuki Arima Tiscoski Allan Covens Lara De Guerké Prafull Ghatage Lucy Gilbert Susie Lau Amit M. Oza Diane Provencher Omar Touhami Congzhu Li Danbo Wang Ge Lou Zhu Genhai Guiling Li Shi Hong Hong Zheng Hongwu Wen Jihong Liu Jing Wang Ke Wang Kui Jiang Li Li Wang Li Min Hao Qi Zhou Gao Qinglei Sihai Liao Songling Zhang Weidong Zhao Xiaohua Wu Wuliang Wang Rutie Yin Ying Cheng Yu Zhang Zhiqing Liang Fernando Contreras Mejía Ángel Luis Martín de Francisco Hernández Carolina Ortiz Lopez Carlos Javier Pacheco Pedro Luis Ramos Guette Jaime Rendon Pereira Julian Rivera Diaz Tomás Sánchez Villegas

Immunotherapy and chemotherapy combinations have shown activity in endometrial cancer, with greater benefit mismatch repair (MMR)-deficient (dMMR) than MMR-proficient (pMMR) disease. Adding a poly(ADP-ribose) polymerase inhibitor may improve outcomes, especially pMMR

10.1200/jco.23.02132 article EN cc-by-nc-nd Journal of Clinical Oncology 2023-10-21

The formulation of BCS Class II drugs as amorphous solid dispersions has been shown to provide advantages with respect improving the aqueous solubility these compounds. While hot melt extrusion (HME) and spray drying (SD) are among most common methods for production (ASDs), high temperatures often required HME can restrict processing thermally labile drugs, while use toxic organic solvents during SD impact on end-product toxicity. In this study, we investigated potential supercritical fluid...

10.1021/mp500644h article EN Molecular Pharmaceutics 2015-03-02

ABSTRACT Purpose In October 2018, the OPTN changed adult heart transplant (HT) allocation policy, increasing number of candidates that had higher priority than pediatric candidates, potentially disadvantaging waitlist registrants. Methods To understand impact this policy change, we used SRTR data to identify 1469 pre‐policy (7/2016–9/2018) and 2901 (10/2018–12/2022) post‐policy (< 18 years) HT We quantified mortality risks using weighted cause‐specific hazard models, then competing...

10.1111/petr.14904 article EN Pediatric Transplantation 2025-01-08

ABSTRACT Introduction Some living organ donors will decide to donate again at a later date. Evidence has indicated that this practice may have increased in recent years. We evaluated the incidence and outcomes of inform counseling potential repeat donors. Methods Using SRTR data from 1994 2023, we identified 220 their 415 recipients. constructed donor comparison groups using weighting by odds. described clinical lab results 6 months, 1 year, 2 years post‐donation separately for kidney‐second...

10.1111/ctr.70049 article EN Clinical Transplantation 2025-01-01

ABSTRACT Background Parents of pediatric heart transplant (HTx) recipients have a unique perspective on the challenges associated with transition into adult care networks. We sought to assess parental perceptions HTx face daily and concerns around from Methods A 15‐item online survey was developed in partnership parent‐stakeholders administered parents September 2023. Closed open‐ended questions assessed (1) patients' diagnosis, age at transplant, (2) parents' about their child's well‐being,...

10.1111/petr.70062 article EN Pediatric Transplantation 2025-03-14

ABSTRACT Introduction Predicting graft failure risk in pediatric liver transplantation (LT) recipients could identify areas for improving management. Persistent cognitive, motor, academic, and functional deficits are common their impact on survival following LT helps inform prediction. Methods Using SRTR data 2008–2023, we evaluated the of at time transplant to 14 years post‐LT. We compared all cause (ACGF) among patients with versus without pre‐LT 1‐year post‐LT using Cox regression,...

10.1111/ctr.70132 article EN Clinical Transplantation 2025-03-28

5512 Background: DUO-E (NCT04269200) showed statistically significant and clinically meaningful progression-free survival (PFS) with carboplatin/paclitaxel (CP) plus durvalumab (D) followed by D (CP+D) ± maintenance olaparib (O) vs CP in endometrial cancer (intent-to-treat [ITT] population; primary endpoints). The greatest benefit for CP+D was mismatch repair deficient (dMMR) patients (pts); addition of O (CP+D+O) further enhanced PFS MMR proficient (pMMR) pts (prespecified exploratory...

10.1200/jco.2025.43.16_suppl.5512 article EN Journal of Clinical Oncology 2025-05-28

Current experimental methodologies used to determine the thermodynamic solubility of an API within a polymer typically involves establishing dissolution/melting end point crystalline physical mixture or through use glass transition temperature measurement demixed amorphous solid dispersion. The measurable "equilibrium" points for are normally well above system, meaning extrapolation is required predict drug at pharmaceutically relevant temperatures. In this manuscript, we argue that presence...

10.1021/acs.molpharmaceut.7b00445 article EN Molecular Pharmaceutics 2017-12-05

The Coxian phase-type distribution is a special type of Markov model which can be utilised both to uncover underlying stages survival process and make inferences regarding the rates flow individuals through these latent before an event interest occurs. Such models utilised, for example, identify who are likely deteriorate faster series disease states thus require more aggressive medical intervention. Within this paper, two-stage approach analysis longitudinal data presented. In Stage 1,...

10.1177/0962280217706727 article EN cc-by Statistical Methods in Medical Research 2017-06-20

<h3>Introduction/Background</h3> Combination of immunotherapy with carboplatin/paclitaxel (CP) has demonstrated improved progression-free survival (PFS) and overall (OS) in patients advanced endometrial cancer. The Phase III DUO-E/GOG-3041/ENGOT-EN10 trial (NCT04269200) evaluated the addition durvalumab to standard first-line CP, followed by ± olaparib, <h3>Methodology</h3> Patients newly diagnosed Federation Gynecology Obstetrics Stage III/IV or recurrent cancer naïve systemic treatment...

10.1136/ijgc-2024-esgo.31 article EN 2024-03-01

Background: The Extracorporeal Life Support Organization Supplies Platform (https://Supplies.ELSO.org) was created out of Membrane Oxygenation (ECMO) disposable product shortage prior to and during the Coronavirus Disease 2019 (COVID-19) pandemic. This novel supports Centers in obtaining disposables from other when alternative avenues are exhausted. Methods: Driven by opportunity for increased patient care using availability 962 ELSO centers worldwide motivation form an efficient online...

10.1051/ject/2023001 article EN cc-by Journal of ExtraCorporeal Technology 2023-02-03

ABSTRACT Background Pretransplant functional, motor, cognitive, and academic deficits are common in pediatric patients requiring heart transplantation (HT); some persist post‐HT. We assessed the association between these quality of life (QoL) post‐HT outcomes. Methods Using SRTR data 2008–2023, we evaluated status HT recipients from listing to 15 years compared all‐cause graft survival among with vs. without pre‐HT using Cox regressions. Among a functioning at 1 year, that time subsequent...

10.1111/petr.14874 article EN Pediatric Transplantation 2024-11-25

Abstract The mixing of process streams with large differences in temperature, typically on the order 300°F (150°C) or greater, can result cracking due to thermal fatigue. Over years, and failures these “thermal mix points” have been reported, but little way estimating life, probability cracking, has published outside nuclear industry, where this form a major issue. This paper describes evaluation fatigue model, originally applied problems piping, for use petrochemical applications....

10.5006/c2012-01134 article EN CORROSION 2012-03-11
Coming Soon ...